A Phase 1-2 Study Of Combination Therapy With INCMGA00012 (Anti PD-1), INCAGN02385 (Anti LAG-3), And INCAGN02390 (Anti TIM-3) In Participants With Select Advanced Malignancies Read more
A Phase 1 Study Exploring The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of INCB099318 In Participants With Select Advanced Solid Tumors Read more
A Multicenter, Open-Label, Phase I/II Study Of EOS884448 In Combination With Standard Of Care And/Or Investigational therapies In participants With Advanced Solid Tumors Read more
A Phase 2 Study Of Erdafitinib In Subjects With Advanced Solid Tumors And Selected FGFR Gene Alterations. Read more
A Phase 1, Open-Label, Multiple-Ascending Dose Study Of The Safety And Tolerability Of CTX-471 In Patients With Inadequate Responses To PD-1/PD-L1 Checkpoint Inhibitors In Metastatic Or Locally Advanced Malignancies Read more
A Phase 1b, Open-Label, Dose Escalation Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of MK-0482 As Monotherapy And In Combination With Pembrolizumab In Participants With Advanced/Metastatic Solid Tumors. Read more
A Phase 1/2 Study Of CPI-0209 Monotherapy And In Combination With Other Therapy In Patients With Advanced Tumors Read more
Master Study: A Phase 2, Umbrella Study with Rolling Arms of Investigational Agents with either Pembrolizumab in Combination with Chemotherapy or with Pembrolizumab Alone in Patients with Advanced Non-small Cell Lung Cancer (NSCLC) KEYMAKER-U01 Substudy 1: A Phase 2, Umbrella Study with Rolling Arms of Investigational Agents with Pembrolizumab in Combination with Chemotherapy in Treatment-Naïve Patients with Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A) – NCT04165070 KEYMAKER-U01 Substudy 2: A Phase 2, Umbrella Study with Rolling Arms of Investigational Agents in Combination with Pembrolizumab in Treatment Naïve Patients with PD-L1 Positive Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01B) – NCT04165083 KEYMAKER-U01 Substudy 3: A Phase 2, Umbrella Study with Rolling Arms of Investigational Agents in Combination with Pembrolizumab in Patients with Advanced Non-small Cell Lung Cancer (NSCLC) Previously Treated with anti-PD-(L)1 Therapy (MK-3475-01C) – NCT04165096 A Phase 2, Umbrella Study with Rolling Arms of Investigational Agents with either Pembrolizumab in Combination with Chemotherapy or with Pembrolizumab Alone in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Read more
